首页> 外文期刊>Therapeutic Drug Monitoring >Poor Performance of Laboratories Assaying Newly Developed Antiretroviral Agents: Results for Darunavir, Etravirine, and Raltegravir From the International Quality Control Program for Therapeutic Drug Monitoring of Antiretroviral Drugs in Human Plasma/Serum
【24h】

Poor Performance of Laboratories Assaying Newly Developed Antiretroviral Agents: Results for Darunavir, Etravirine, and Raltegravir From the International Quality Control Program for Therapeutic Drug Monitoring of Antiretroviral Drugs in Human Plasma/Serum

机译:检测新开发的抗逆转录病毒药物的实验室性能不佳:国际质量控制计划中针对人血浆/血清中抗逆转录病毒药物的国际质量控制计划提供的Darunavir,Etravirine和Raltegravir的结果

获取原文
获取原文并翻译 | 示例
           

摘要

Background: The International Interlaboratory Quality Control Program for Therapeutic Drug Monitoring of Antiretroviral Drugs in Human Plasma/Serum was initiated in 1999. We have previously published our experience during the first 10 years of the Program. Since 2010, 3 newly developed antiretroviral agents have been added to the Program: darunavir, etravirine, and raltegravir. The objective of this analysis is to describe the performance of participating laboratories measuring these newer agents in 2011-2012.
机译:背景:针对人血浆/血清中抗逆转录病毒药物的治疗性药物监测的国际实验室间质量控制计划于1999年启动。我们此前已在该计划的前10年中发表了我们的经验。自2010年以来,该程序已添加了3种新开发的抗逆转录病毒药物:darunavir,etravirine和raltegravir。该分析的目的是描述参与实验室在2011-2012年间评估这些较新试剂的性能。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号